Hva koster H. Lundbeck A/S aksje i dag?

aksjekurs for H. Lundbeck A/S (0ND5.IL) er 43,04 DKK i dag. Prisen oppdateres løpende i handelstiden, og du kan følge historisk kursutvikling på denne siden.

0ND5.IL er tickersymbolet for H. Lundbeck A/S. Symbolet brukes til å identifisere instrumentet på børsen.

Bør jeg kjøpe H. Lundbeck A/S nå?

Det avhenger av investeringsstrategi, risikoprofil og tidshorisont. Se analytikernes anbefalinger, kursmål og tekniske signaler på denne siden før du investerer.

Hva sier analytikerne om H. Lundbeck A/S?

Analytikernes vurderinger av H. Lundbeck A/S (0ND5.IL) bygger på fundamental analyse, verdsettelse og markedsforhold. Her finner du en samlet oversikt.

H. Lundbeck A/S (H LUNDBECK A/S H.LUNDBECK ORD S) aksje

0ND5.IL

43.04 kr.-0.40 (-0.92%)

Laster graf...

H LUNDBECK A/S H.LUNDBECK ORD S

Market Cap

$43,129,524,224

Åpning0.00

Høy0.00

Lav0.00

Volum

P/E17.50

Markedsverdi43.13B

52-ukers høy47.44

52-ukers lav0.00

Gj.sn. volum95.89k

Utbytte1.58%

BetaN/A

EPS2.46

Om H. Lundbeck A/S (H LUNDBECK A/S H.LUNDBECK ORD S) aksje

H. Lundbeck A/S, a biopharmaceutical company, engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company's principal products include Abilify Maintena for schizophrenia; Brintellix/Trintellix to treat depression; Northera for the treatment of symptomatic neurogenic orthostatic hypotension; Vyepti for migraine prevention; and Rexulti/Rxulti to treat depression/schizophrenia. It also provides Azilect for treating Parkinson's disease; Cipralex/Lexapro for depression; Ebixa to treat Alzheimer's disease; Onfi for Lennox-Gastaut syndrome; Sabril for treating epilepsy; and Xenazine for chorea associated with Huntington's disease, as well as other products. The company sells its products primarily to distributors of pharmaceuticals, pharmacies, and hospitals. It has a partnership collaboration with Otsuka Pharmaceuticals Co., Ltd.; and collaboration with FeetMe focusing on the use of sensor shoe soles. H. Lundbeck A/S also has a collaboration with Alloy Therapeutics, Inc. for the discovery of novel biologics therapies. The company was founded in 1915 and is headquartered in Valby, Denmark.